Pedraza MA, Olvera GCI, Aguirre SJS, Camarena AG, Franco GJ

Language: Spanish
References: 9
Page: 55-59
PDF size: 207.21 Kb.

ABSTRACT

Introduction: Candidemia is a clinical entity increasing in patients in intensive care unit, the inmuncompromised and multiple invasion makes them subject of fungal dissemination and increase in mortality. Use of scores to estimate the risk of developing candidemia has allowed start prophylactic antifungal azoles; however, the development of Candida albicans has not increased, generating uncertainty about the benefit that can have these measures initiated in early mortality.
Objectives: To determine whether patients who received prophylactic any antifungal azole has impact on the development of Candida non-albicans in patients admitted to the intensive care unit.
Methods: A retrospective, longitudinal, analytical study. Patients over 18 years enter the intensive care unit with sepsis. Determined that patients received prophylactic azoles and those who have developed Candida albicans and non-albicans.
Statistical analysis: Statistical analysis was performed using Student T for comparison group and χ² for categorical variables. The results are expressed in average, ±, standard deviation and percentage. It is considered statistically significant if p ≤ 0.05, analysis using statistical system SPSS Statistics 21.
Results: 25 patients, 2-year period, age 72 ± 13 years (45-92), 15 men (60%), abdominal sepsis 56% (n = 14), APACHE II 14 ± 5 (5-29) and SOFA 6 ± 3. Culture without growth in 16 patients (64%), Candida albicans 4 (16%) and non albicans in 5 (20%).
Conclusions: The incidence of Candida albicans in patients not receiving prophylaxis with fluconazole is low, with no increase in mortality, and we believe that the use of fluconazole as prophylactic management remains an appropriate measure in this group.

REFERENCES

1. Jabeen K, Kumar H, Farooqi J, Mehboob R, Brandt M, Zfar A. Agreement of direct antifungal susceptibility testing from positive blood culture bottles with the conventional method for Candida Species. J Clin Microb. 2016;54(2):343-348.

2. Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E. Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection. 2015; pp. 1-9.

3. Peron IH, Reichert-Lima F, Busso-Lopes AF, Nagasako CK, Lyra L, Moretti ML, et al. Resistance surveillance in Candida albicans: A five-year antifungal susceptibility evaluation in a Brazilian University Hospital. PLoS One. 2016;11(7): e0158126.

4. Vila T, Romo JA, Pierce CG, McHardy SF, Saville SP, Lopez RJ. Targeting Candida albicans filamentation for antifungal drug development. Virulence. 2017;8(2):150-158.

5. Vallabhaneni S, Cleveland AA, Farley MM, Harrison LH, Schaffner W, Beldavs Z, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008-2014. Open Forum Infect Dis. 2015;2(4):ofv163.OFID.

6. Mohammadi R, Foroughifar E. Candida infections among neutropenic patients. Caspian J Intern Med. 2016;7(2):71-77.

7. Tadec L, Talarmin J, Gastinne T, Bretonniere C, Miegeville M, Le Pape P, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study. Mycoses. 2016;59:296-303.

8. Asner SA, Giuleri S, Diezi M, Marchetti O, Sanglard D. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother. 2015;59(12):7715-7722.

9. Zaidi KU, Mani A, Thawani V, Mehra A. Total protein profile and drug resistance in Candida albicans isolated from clinical samples. Mol Biol Int. 2016;2016:4982131.